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standardized questionnaires/tests will be applied for de-
tailed neuropsychological assessment. In addition, patients 
will be asked to participate in modules including volumetric 
MRI, genetic parameters, and neuropsychology to detect 
risk factors, early diagnostic biomarkers and predictors for 
dementia in PD.  Results: The study included 604 PD patients 
by March 2011; 56.3% were classified as having PD alone, 
with 30.6% of patients suffering from PD-MCI and 13.1% 
from PD with dementia. The mean age of the cohort was 68.6 
 8 7.9 years, with a mean disease duration of 6.8  8 5.4 years. 
There was a prepon derance of patients in the earlier Hoehn 
and Yahr stages.  Conclusion: The main aim of the study is to 
characterize the natural progression of cognitive impair-
ment in PD and to identify factors which contribute to the 
evolution and/or progression of the cognitive impairment. 
To accomplish this aim we established a large cohort of PD 
patients without cognitive dysfunction, PD patients with 
MCI, and PD patients with dementia, to characterize these 
patients in a standardized manner, using imaging (serial 
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 Abstract 
 Background: Parkinson’s disease (PD) is a progressive neu-
rodegenerative motor disorder. However, non-motor com-
plications frequently alter the course of the disease. A par-
ticularly disabling non-motor symptom is dementia.  Meth-
ods/Design: The study is designed as a multicentre 
prospective, observational cohort study of about 700 PD pa-
tients aged 45–80 years with or without dementia and PD-
mild cognitive impairment (MCI). The patients will be recruit-
ed in eight specialized movement disorder clinics and will
be followed for 36 months. Information about the patients’ 
functional status will be assessed at baseline and 6-/12-
month intervals. In addition, 120 patients with dementia 
with Lewy bodies (DLB) will be included. Well-established 
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structural MRI), genetic and proteomic methods in order to 
improve our understanding of the course of the PD process 
and the development of cognitive dysfunction and demen-
tia in this disease. The inclusion of the DLB patients will start 
in the second quarter of 2011 in the BMBF-funded follow-up 
project LANDSCAPE.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Parkinson’s disease (PD) is one of the most common 
neurodegenerative disorders with an incidence that rises 
with age and a lifetime risk of developing the disease of 
1.5%  [1] . For Europe, the crude incidence rates reported 
in various studies and populations range from 5/100,000 
to 26/100,000  [2] .
 PD is characterized clinically by rigidity, tremor, bra-
dykinesia and impaired postural reflexes. In addition to 
these motor features, non-motor symptoms such as psy-
chiatric disorders, autonomic disturbances and sleep dis-
orders frequently complicate the course of the disease.
A particularly disabling non-motor complication of PD 
with a strong impact not only on the patients but also on 
their families and caregivers is dementia. Aarsland et al. 
 [3] stated the prevalence of dementia in PD (PD-D) to be 
0.5% in subjects older than 65 years for the general popu-
lation, accounting for 3.6% of all dementia cases. There is 
increasing evidence that PD-D is a more common non-
motor complication than previously thought: about 30% 
of PD patients suffer from cognitive impairment and de-
mentia  [3–6] . A recent 12-year follow-up of a longitudinal 
cohort study in Norway found the life expectancy of a 
70-year-old man with PD but no dementia to be 8 years, 
of which 5 years are expected to be dementia-free and 3 
years are expected to be with dementia; for a female PD 
patient, the life expectancy is 11 years, of which about 7 
are expected to be without, and approximately 4 years are 
expected to be with dementia. If a PD patient at the age 
of 70 had already developed dementia, the life expectancy 
was found to be reduced to about 4 years in the male, and 
to 5.7 years in the female patient  [7] . 
 The natural history of PD-D, however, starting from
a mild executive dysfunction  [8] to a more generalized 
cognitive impairment and dementia, has not yet been
fully explored in longitudinal designs with sufficient-
ly large samples. Furthermore, current clinical criteria 
distinguish dementia with Lewy bodies (DLB) and PD-D 
exclusively by the temporal requirement that parkinson-
ism precedes dementia by more than 12 months in PD-D, 
while DLB is assumed if dementia occurs before or con-
currently with motor symptoms of PD  [9] . However, it is 
not clear to what extent the two different PD types differ 
in their course and outcome and to what degree they dif-
fer in associated risk factors. The prevalence of DLB is 
assumed to be high, although reliable estimates are cur-
rently lacking. In the population of all demented patients, 
DLB is estimated to represent between 0 and 30.5% of 
cases  [3] . In a group of PD patients with an age at disease 
onset of about 70 years, the prevalence of dementia 8 
years later was reported to be more than 75%  [10] .
 The Dementia and Parkinson’s Disease (DEMPARK) 
consortium will focus on the topic of PD and PD-D to 
monitor the progress of PD and the development of cog-
nitive dysfunction in a large cohort of PD patients over 36 
months, recruited in eight specialized German centres. 
The overall main aim is to characterize the natural pro-
gression of cognitive impairment in PD and to identify 
factors which contribute to the evolution and/or progres-
sion of the cognitive impairment.
 By applying a specifically composed neuropsycholog-
ical test battery, PD patients will be allocated to three sub-
groups: (1) PD patients without cognitive impairment 
(PD); the diagnosis ‘idiopathic PD’ will be made accord-
ing to the UK Parkinson’s Disease Society Brain Bank 
clinical diagnostic criteria  [11] . (2) PD patients with mild 
cognitive impairment (PD-MCI); the MCI criteria of Pe-
tersen  [12] with all subclasses will be applied. (3) PD pa-
tients with dementia (PD-D). The consensus guidelines 
by Emre et al.  [13] will be applied.
 The DEMPARK consortium aims to build a large co-
hort of patients with PD, PD-MCI and PD-D (n  6 700 
patients), which will represent the largest ever studied na-
tional cohort of PD patients without and with dementia. 
All patients in the cohort will be subjected to serial stan-
dardized neurological and neuropsychological testing (at 
baseline, and at two follow-ups after 6 and 12 months, 
respectively) and will thus provide a well-characterized 
cohort of patients. Recently, the study was extended to 
follow the PD cohort for two more years (24 and 36 
months after enrolment) and to include also patients with 
DLB(n = 120), which will start to recruit patients in this 
indication in the second quarter of 2011. The study will 
be renamed with the eponym ‘LANDSCAPE’ (Langzeit-
beobachtung dementieller Symptome und cognitiver Pa-
rameter sowie Anwendbarkeit neuer prognostischer 
Marker bei der Parkinson-Erkrankung) and is part of the 
Competence Network Degenerative Dementias, funded 
by the German Ministry for Education and Research 
(BMBF).
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 Besides the cohort study, patients will be asked to par-
ticipate in add-on modules to the study (i.e. MRI at base-
line and after 12 months; a genetic module with collec-
tion of blood DNA (at baseline) and blood RNA samples 
(at baseline and after 6 and 12 months), as well as neuro-
psychological testing for cognitive plasticity (at baseline 
and at 12 months). 
 The collection of a large number of blood samples (se-
rum, plasma, blood DNA, and blood RNA) of well-char-
acterized patients will provide a unique source for the 
search for risk factors, predictors and early differentiat-
ing markers for early detection of developing dementia in 
PD as well as for defining the role of Alzheimer’s disease 
and Lewy body pathology in dementia in PD.
 Methods 
 Design of the Study 
 The study is a multicentre, prospective, observational cohort 
study of PD patients. Patients will be consecutively recruited in 
eight specialized movement disorder centres distributed across 
Germany (Aachen, Bonn, Dresden, Frankfurt/Main, Kassel, Kiel, 
Marburg and Tübingen). All patients who are willing to partici-
pate and who fulfil the inclusion criteria will be included in the 
study. Each study centre will recruit consecutively 80–100 PD pa-
tients with or without dementia within 12 months. In addition, 
120 patients with DLB will be recruited. In patients not willing to 
participate, an anonymous minimal data set (gender, age, Hoehn 
and Yahr  [14] stage and, if available, a Mini-Mental State Exami-
nation (MMSE) score  [15] not older than 3 months) will be col-
lected to avoid systematic inclusion errors.
 The study centres began screening and enrolment of PD pa-
tients during the 3 months from November 2009 to January 2010. 
 Sample Size 
 Based upon the main outcomes of this project (see below) and 
the conversion rates of cognitive decline in PD patients as report-
ed by Aarsland et al.  [3] , we estimated that a sample size of n = 500 
would be sufficient for the investigation. This was confirmed by 
conservative power analyses (  = 0.05, two-sided; power  1 99.9%). 
As we expect 10% of patients to be ineligible due to exclusion cri-
teria and 15% of patients to drop out over time, 700 patients must 
be included initially to provide 500 completers after 12 months 
(i.e. each study centre will recruit 80–100 PD patients with or 
without dementia during this period). Based on the prevalence 
and conversion rates of MCI and PD-D, the sample will be strati-
fied into 250 patients without cognitive impairment, 200 patients 
with MCI, and 250 patients with dementia  [12] . In addition, we 
included the recruitment of 120 patients with DLB. 
 Regarding the expected conversion rates, we estimated based 
on our own and data from the literature an expected 18-month 
incidence and 3-year incidence among baseline unaffected and 
MCI, respectively, for cognitive impairment/dementia. Thus, we 
expect conservatively a total number of patients converted to de-
mentia of 69 patients at the first follow-up and 108 at the 3-year 
follow-up. 
 Inclusion Criteria 
 To be eligible for enrolment in the DEMPARK study, partici-
pants must be between 45 and 80 years of age, must meet criteria 
for the diagnosis ‘idiopathic PD’ according to the UK Parkinson’s 
Disease Society Brain Bank clinical diagnostic criteria  [11] or the 
diagnosis ‘idiopathic PD with MCI’ according to the criteria giv-
en by Petersen  [16] or the diagnosis ‘idiopathic PD with dementia’ 
according to the consensus guidelines developed by Emre et al. 
 [13] and operationalized by Dubois et al.  [17] . 
 MCI criteria by Petersen  [16] require: (1) a subjective complaint 
of cognitive decline by the patient, preferably corroborated by a 
reliable source; (2) minimal impact of the decline on day-to-day 
functioning and the absence of dementia (both primarily based on 
clinical interview and history), and (3) ‘objective’ evidence of cog-
nitive abnormalities that cannot be simply attributed to age. In this 
study we included all subclasses including amnestic MCI single 
domain, amnestic MCI multiple domain, non-amnestic MCI sin-
gle domain, and non-amnestic MCI multiple domain. For the di-
agnosis of PD-D, the following characteristics are required  [13] : (1) 
core features, (2) associated features, (3) features which do not ex-
clude PD-D, but make the diagnosis uncertain, and (4) features 
suggesting other conditions or diseases as cause of mental impair-
ment, which, when present make it impossible. Accordingly, pa-
tients with probable PD-D and possible PD-D were included. 
 For the extension of the DEMPARK study, the so-called 
LANDSCAPE study, an additional cohort of patients was includ-
ed with the diagnosis DLB according to the criteria by McKeith et 
al.  [9] . To be classed as having cognitive impairment (PD-D, DLB), 
the patient must score an MMSE of  ̂  28 to 17 points, and a Par-
kinson Neuropsychometric Dementia Assessment (PANDA)  ̂  17 
points in the initial screening. PANDA has been developed as a 
screening tool for cognitive and affective complications in PD 
 [18] . In short, the PANDA assesses functions that are typically af-
fected in PD on five subscales: word pair associate learning with 
immediate (task 1) and delayed recall (task 5), alternating verbal 
fluency task (task 2), visuospatial task (task 3) and working mem-
ory and attention task (task 4) – for a maximum score of 30 points. 
If test results are  6 18 points, this reflects a normal cognitive 
function level, 15–17 points suggest ‘mild cognitive dysfunctions’ 
and any score below 15 indicates ‘severe cognitive impairment’, 
indicative of dementia.
 Exclusion Criteria 
 Patients will be excluded for the following reasons: diagnosis 
of or evidence for atypical Parkinson syndromes (e.g. Multiple 
System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), 
Cortical-Basal Degeneration (CBD); other causes of dementia 
based on clinical grounds (e.g. Alzheimer’s disease, vascular de-
mentia, frontotemporal dementia, Creutzfeldt-Jakob disease, 
Huntington’s Disease); PD patients with severe cognitive impair-
ment that impedes consent; medical and ethical reasons in rela-
tion to the morphological and neurobiological examinations; 
pregnant patients.
 Clinical Assessment 
 Patient-based exposures to be assessed in the DEMPARK 
study fall into two major categories: cohort study and/or add-on 
modules (genetic, imaging or neuropsychological testing). 
 The patients will be followed up at 6-month intervals for 12 
months followed by further annual follow-ups for a total period 
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of 3 years; the types of assessment as well as the time(s) of assess-
ment are shown in  table 1 .
 Patient-based exposures assessed at the time of study enrol-
ment (=baseline) comprise three major sections. Section A docu-
ments patient demographics such as age, gender, marital status, 
and grade of education. Section B documents PD diagnosis, incor-
porating the Clinical Global Impression scale  [19] of PD severity, 
and parts I (Mentation, Behaviour, and Mood), III (Motor Exami-
nation), and IV (Complications) of the Unified Parkinson’s Dis-
ease Rating Scale  [20] , severity of illness (Hoehn and Yahr  [14] 
 stage), and comorbidities as well as medications taken over the 3 
months before enrolment. Information about the duration of PD 
symptoms, the date of initial diagnosis, and the start of initial PD 
drug therapy as well as a family history with respect to PD will also 
be recorded. Section C consists of scales and ratings for the neu-
ropsychological assessment of the patients. The selection of the 
cognitive outcome measures was done by a group of neuropsy-
chologists and clinicians with experience in the evaluation of cog-
nitive impairment in basal ganglia disorders and followed closely 
current recommendations  [13, 17, 21] : the CERAD plus test battery 
 [22] with nine subtests (learning of word lists, recall, and recogni-
tion, letter fluency and semantic verbal fluency, Boston Naming 
Test, construction, recall of drawn figures, Trail Making Test parts 
A and B) that assess verbal short- and long-term as well as non-
verbal long-term memory, executive functions, language, visuo-
constructive abilities, and orientation. The subtests digit span for-
ward and reverse from the revised Wechsler Memory Scale  [23] 
will be used to assess working memory. Executive functions will 
be further tested by Stroop colour word test [27] and the Modified 
Card Sorting Test  [24] , and visuospatial performance with subtests 
7 and 9 (spatial rotation, spatial imagination) of the German intel-
ligence test battery ‘Leistungsprüfsystem’ (LPS 50+)  [25] . Atten-
tion will be assessed with the Brief Test of Attention  [26] and the 
Stroop colour word test  [27] . The short form of the geriatric de-
pression scale  [28] , a 15-item self-evaluation questionnaire, will be 
used to assess depression. Apathy will be evaluated using the apa-
thy evaluation scale, which treats it as a psychological dimension 
defined as ‘a state characterized by simultaneous diminution in 
the overt behavioural, cognitive, and emotional concomitants of 
goal-directed behaviour’  [29] . Health-related quality of life will be 
assessed using the EQ-5D  [30] , which has five sections relating to 
mobility, self-care, usual activities, pain/discomfort and anxiety/
depression as well as a visual analogue scale for patients to indicate 
their own perception of their state of health. The Parkinson’s Dis-
ease Questionnaire (PDQ-39)  [31] will be used as a PD-specific 
measure of health-related quality of life, consisting of 39 questions, 
which cover eight aspects of quality of life (mobility, activities of 
daily living, emotional well-being, stigma, social support, cogni-
tion, communication, bodily discomfort).
 Add-On Modules of the DEMPARK Study 
 Genetic Module  
 It is hypothesized that synucleinopathies including PD and 
PD-D are caused by the dysregulation of intracellular   -synucle-
in that leads, via still unknown mechanisms of protofibril forma-
tion and aggregation, to cell type-specific neuronal dysfunction 
and cell death. PD itself is heterogeneous in its aetiology, and there 
is evidence that different genetic risk factors for PD may be asso-
ciated with a different risk for dementia in PD. For example, pa-
tients with autosomal dominantly inherited PD due to point mu-
tations in SNCA, the gene encoding   -synuclein, have a high prev-
alence of dementia  [32, 33] , as have patients with triplications of 
the SNCA locus  [34] . Likewise, patients with mutations in the gene 
for glucocerebrosidase, the gene causing Gaucher’s disease and 
predisposing to PD  [35] , appear to have a higher prevalence of de-
mentia, whereas patients with LRRK2-associated PD seem to 
have a somewhat lower risk for cognitive impairment, compared 
to PD in general  [36] . It is likely that genetic factors also have a 
Table 1.  Assessments in the DEMPARK study
Exposure/
instrument
Time(s) of
assessment
Demographics, baseline diagnosis, medical history
Questionnaire BL
Medications
Questionnaire BL, FU1, FU2
Health status
Patient examination BL, FU2
Neurological status
Patient examination BL, FU2
Comorbidities
Charlson Comorbidity Index BL, FU2
Severity of illness
Hoehn and Yahr Scale [14] screening
Clinical assessment
UPDRS (I, III, IV) [20] BL, FU1, FU2
Clinical Global Impression [19] BL, FU2
Neuropsychological test battery
MMSE [15, 57] screening, FU2
PANDA [18, 58] screening, FU1, FU2
CERAD-Plus [22] BL, FU2
Brief Test of Attention [26] BL, FU2
Wechsler Memory Scale-R [23] BL, FU2
Modified Card Sorting Test [24] BL, FU2
Stroop Test [27] BL, FU2
LPS 50+ [25] BL, FU2
Depression
Geriatric Depression Scale,
short form [28] BL, FU2
Apathy
Apathy Evaluation Scale [29] BL, FU2
Quality of life/health status
EQ-5D [30] BL, FU2
PDQ-39 [31] BL, FU2
Blood sampling
Blood sampling for serum and plasma BL, FU1, FU2
Imaging module
cMRI BL, FU2
Genetic module
Blood sampling for DNA BL
Blood sampling for RNA BL, FU1, FU2
Cognitive plasticity module BL
B L = Baseline; FU1 = first follow-up 1 (6 months after enrol-
ment); FU2 = second follow-up (12 months after enrolment).
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profound influence on whether and when a patient with PD de-
velops dementia. Knowledge of these factors will be important for 
identifying specific subgroups at risk when disease-modifying 
treatments become available. Therefore, this subproject aims to 
investigate candidate genes for their association with dementia in 
this prospectively characterized cohort and to perform a genome-
wide association study with the endophenotype of dementia as 
well as with other endophenotypes characterized in this study, 
and thus to identify novel risk genes.
 The aim of this project is therefore to identify the genetic deter-
minants of the development of dementia in patients with PD. Blood 
samples for DNA isolation will be taken at baseline from patients 
who participate in the genetic add-on module, as well as blood sam-
ples for RNA isolation at baseline and both follow-ups ( table 1 ).
 Imaging Module  
 It is hypothesized that PD patients who develop dementia rep-
resent a subgroup within the PD spectrum that is characterized 
by the early occurrence of neuropsychological and morphological 
or functional brain abnormalities. Therefore, we will perform a 
longitudinal MRI study to identify imaging alterations and their 
correlations with neuropsychological features and other bio-
markers. Finally, we aim to determine the predictive value of MRI 
changes for the development and progression of dementia in the 
PD cohort. The MRI investigations will be conducted at 3 T field 
strength and refer to different aspects of brain morphology and 
functioning: global and local brain atrophy and grey matter loss 
(T 1 MPRAGE, T 1 and T 2 * relaxometry), total load and strategic 
localization of vascular white matter hyperintensities (PD/T 2 TSE 
sequences), disintegration of white matter fibres (DWI and DTI) 
and dysfunction of the so-called resting state network activity of 
the brain (fMRI). In a common and standardized MRI data ac-
quisition approach, T 1 MPRAGE and PD/T 2 TSE  sequences will 
be acquired in each of the study centres with direct access to a 
3-tesla MRI scanner (Frankfurt/Main, Bonn, Dresden, Mar-
burg). In addition, each imaging centre has designed additional 
local projects dealing with new MRI techniques or special re-
search questions, which will be added to the standard multicentre 
MRI sequences. 
 All participants in the imaging module will receive two MRI 
scans, one at baseline (within 14 days after enrolment) and one af-
ter a 1-year follow-up period ( table 1 ). After image transfer to one 
centre (Frankfurt/Main), data will be analysed by blind -ed inves-
tigators according to region of interest and voxel-based methods.
 Cognitive Plasticity Module 
 ‘Cognitive plasticity’ is a concept that is open to direct testing. 
It refers to the learning potential and the potential of cognitive 
performance after directed interventions  [37] . Specific neuropsy-
chological paradigms have been developed to operationalize cog-
nitive plasticity. In contrast to common ‘static’ tests, which result 
in an absolute measure of cognitive performance (e.g. ‘remembers 
a mean of 5 out of 10 words in a word list learning paradigm’), 
these ‘dynamic tests’ or ‘testing the limits’ instruments assess the 
dynamics of the individual learning curve during the task in 
which interventions for cognitive enhancement, for example in 
the form of feedback, reinforcement, or explanation of strategies, 
are integrated. By analysing pre- and post-test measures, the cur-
rent performance can be differentiated from latent reserves for 
cognitive enhancement on an individual basis  [38, 39] . It has been 
shown that learning potential (also called cognitive plasticity) is 
a tool that can be used to discriminate healthy, MCI and AD sub-
jects  [39] ; the learning potential of people with cognitive impair-
ment is diminished compared to cognitively healthy persons. 
 In the participants of the neuropsychological add-on module, 
cognitive plasticity will be assessed at baseline with German ver-
sions of published dynamic tests  [39] for three cognitive domains 
that are typically impaired in PD patients, i.e. verbal memory, 
nonverbal memory, and executive functions  [8, 13] ( table 1 ). In all 
three dynamic tests applied, pre- and post-test trials will be ad-
ministered, with an interval in between in which strategies to en-
hance cognitive performance will be explained to the participant 
with some practice trials. Post- minus pre-test differences will be 
used as indicators of cognitive plasticity. The aim of this study 
module is to examine whether cognitive plasticity might be a pre-
dictor for the development of dementia in PD patients.
 Data Security and Data Quality  
 The interviews/patient examinations will be performed by 
trained scientists and study nurses at the study centres using 
printed forms for data collection. Filled survey sheets will be 
stored in a locker in the study centres. Data will be entered in the 
local centres via an Internet-based remote data entry system 
(Secu trial 3.3)  [40, 42] . The data will be transferred via 128 bit SSL 
encryption. The data will be stored in a central ORACLE database 
on the server farm of the Central Information Office of the Com-
petence Network on Parkinson’s Disease, located in a specially 
secured hosting centre for sensitive data in Fürth, Germany. Ac-
cess to the internal database and web server is controlled by two 
consecutive firewalls and an intrusion detection system. The du-
ties of the hosting system such as daily checks of the access logs, 
security updates, daily backups and storing backup families in a 
bank deposit have been determined in a service level agreement 
contract. An alphanumerical pseudonym (a random combination 
of three letters and three digits) will be automatically created when 
the identification data of a patient are entered, and a printed copy 
with a pseudonym and the identification data for each patient will 
be archived in the individual centres. The identification data will 
neither be electronically transferred nor stored. The members of 
the DEMPARK/LANDSCAPE consortium will be given access to 
the electronic data entry system according to a detailed concept of 
roles and rights upon application. An audit trail will ensure an 
automatic protocol for all data entries, changes and deletions. 
Quality assurance will be performed according to the current 
guidelines of the Telematic Platform for Medical Research (Tech-
nologie- und Methodenplattform für die vernetzte me dizinische 
Forschung e.V.; for details see http://www.tmf-ev.de/Home.aspx). 
 Ethical Approval 
 The study will be conducted in compliance with the Helsinki 
Declaration  [43] . The study protocol was approved by the Ethics 
Committee of Philipps University Marburg (approval No. 178/07) 
in March 2009 and subsequently by the local ethics committees 
of the participating centres.
 Informed Consent  
 Patients can only be included in the study or add-on modules 
after giving their written informed consent. Separate consent is 
required for each module (cohort study, genetic module, cognitive 
plasticity module, and imaging module). 
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 Statistical Analysis 
 This will include prevalence and incidence estimates, crude 
and multiple logistic regression of outcomes on predictors, non-
parametric regression analysis for visualizing patterns of out-
comes on predictors, analysis of time-dependent associations of 
outcomes on predictors by Latent Growth Mixture models, all 
statistical inference account for design aspects (clustering within 
settings, stratification criteria).
 The statistical analyses will be conducted stepwise and in ac-
cordance with the strategy of the program, as follows:
 (1) Descriptive statistics (for example age-related weighted 
prevalence and incidence accounting for strata and clustering 
within settings) in the first stage.
 (2) Nonparametric regression models (local polynomial re-
gression for dimensional variables, generalized additive models 
for categorical variables) for analysing and visualizing the func-
tional form of associations of outcomes on predictors.
 (3) Cross-sectional associations using crude and multiple lo-
gistic regressions (odds ratio and 95% confidence intervals for 
categorical) and univariate and multivariate regressions for di-
mensional variables.
 (4) (Sub-)group comparison (e.g. by age group, PD severity) 
will be conducted – depending on the type of data – with either t 
tests (two-way comparisons of continuous variables) or F tests (for 
categorical or polythetic variables).
 (5) Upon availability of time-related information (either retro-
spective or prospective in follow-up) we plan to use more sophis-
ticated structural equation models to explore the effect of predic-
tor variables on the course of cognitive impairment by using latent 
growth mixture models, which are favoured against the more tra-
ditional ANOVA and MANOVA approach.
 All final statistical modelling and analyses will be conduct -
ed controlling for confounders and the effect of clustering within 
the settings. Descriptive statistics and parametric regression 
models will be conducted by STATA (Stata Corp., 2006), and la-
tent growth mixture models by applying the STATA procedure 
GLAMM  [44] and MPLUS  [45] . Non-parametric estimates of pat-
terns of associations between outcomes and predictors will be
analysed by user-written algorithms in STATA and MATLAB 
(Mathworks Inc., 2006).
 Results 
 A detailed list of the applied instruments and assess-
ments in this study is compiled in  table 1 . As of March 
2011, the study enrolled 604 patients with PD, PD-MCI 
and PD-D ( table  2 ). The enrolment was efficient and 
quick and nearly all centres were able to recruit the pre-
determined number of patients ( fig. 1 ). The mean age of 
the cohort was 68.6 years with 31.8% of the patients being 
female. Mean disease duration was 6.8 years (range: 
1–38). The Hoehn and Yahr stage with the early stages 
was overrepresented with 16% of the patients being in 
stage I, 48% in stage II, 27% in stage III, 8 and 1% in stag-
es IV and V, respectively. The majority of patients had no 
memory impairments (PD: 56.3%) followed by 30.6% of 
the patients having PD-MCI and 13.1% of the patients 
having PD-D. The number of patients recruited for the 
different modules were: module Genetics: 79%; module 
Imaging: 19%; module Cognitive Plasticity: 24%. The re-
cruitment of patients with DLB will be started in the sec-
ond quarter of 2011. 
Table 2.  Baseline characteristics of patients enrolled in the study 
(as of April 2011)
Total patient number 604
PD 56.3%
PD-MCI 30.6%
PD-D 13.1%
Male 68.2%
Female 31.8%
Age at baseline, years 68.687.9 (range: 44–83)
≤65 years 33%
66–75 years 53%
≥76 years 14%
Disease duration, years 6.885.4 (range: 1–38)
Hoehn and Yahr stage
I 16%
II 48%
III 27%
IV 8%
V 1%
Family status
Married/living with partner 83.3%
Divorced 4.6%
Single 3.9%
Widowed 6.9%
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 Fig. 1. Recruitment of PD patients for the DEMPARK cohort. 
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 Discussion 
 Recent epidemiological studies of PD patients suggest 
that dementia is much more common in PD than previ-
ously thought, ranging from estimates of a 10-year prev-
alence of approximately 40%  [5] up to an 8-year preva-
lence of almost 80%  [10] . Cognitive dysfunction may be 
present in more than 20% of newly diagnosed PD patients 
 [46] . The available epidemiological data identified only a 
weak correlation of dementia with the akinetic-rigid syn-
drome; brain morphological changes predicting the de-
velopment of dementia have not yet been identified, de-
spite scientific efforts especially in the field of metabolic 
brain networks  [47–49] .
 Several cohort studies are underway, which, however, 
differ from the study outlined in this communication. 
For example, they have a cross-sectional design, did not 
include a detailed evaluation of cognitive impairment,
focus on a certain cognitive domain or are based on a 
small sample  [6, 50–52] . The Longitudinal and Biomark-
er Study in PD (LABS-PD) is an observational study de-
signed to prospectively measure the evolution of motor 
and non-motor features of PD and samples promising 
biomarkers from early to late-stage illness  [53] . LABS-PD 
is organized on the premise that cohorts from completed 
clinical trials can be re-recruited for long-term follow-up. 
LABS-PD will contain multiple cohorts and will not be 
enriched with the question of PD-D and PD-MCI. 
 The Parkinson’s Progression Markers Initiative 
(PPMI) is an observational research study to identify 
biomarkers of PD progression (http://www.ppmi-info.
org/). This study will use a combination of imaging tech-
niques, collection of blood, urine, and spinal fluid, and 
clinical tests. PPMI requires the participation of 400 
newly diagnosed PD patients not currently taking stan-
dard PD medications and 200 individuals who do not 
have PD. Participants must be at least 30 years of age. 
They will be enrolled at about 18 PD centres – 14 across 
the United States and 4 in Europe – over approximately 
2 years. The goal of the PPMI study is to identify one or 
more biomarkers of PD. The study will not focus on cog-
nitive impairment in those patients, thus not including a 
large battery of cognitive assessments and is not powered 
for the detection of longitudinal evaluation of cognitive 
impairment. Another study aims to investigate the pro-
gression of disability in PD over a 2-year period with 
6-month follow-up periods including 200 PD patients 
 [51] . No evaluation of cognitive impairment is part of 
this study. 
 In contrast, the DEMPARK consortium aims to estab-
lish a large cohort of patients with PD, PD with MCI, and 
PD-D (n  6 700 patients) in Germany. The patients in the 
cohort will be consecutively recruited in eight study cen-
tres (neurological clinics), subjected to serial standardized 
testing (at baseline and two follow-up examinations after 
6 and 12 months) and will thus provide a well-character-
ized cohort of PD, PD-MCI, and PD-D patients. Three 
add-on modules (to search for genetic determinants to de-
velop dementia, serial structural MRI, and neuropsycho-
logical testing of ‘cognitive plasticity’) will provide fur-
ther information about the course of cognitive decline
in PD within the observation period. The collection of
a large number of blood samples (serum, plasma, blood 
DNA, and blood RNA) of well-characterized patients will 
be a unique source for the search for risk factors, predic-
tors and early differentiating markers for the early detec-
tion of developing cognitive dysfunction and dementia in 
PD as well as for defining the role of Alz heimer’s disease 
and Lewy body pathology in dementia in PD.
 Despite a careful and detailed study design, the study 
may have some limitations: 
 (1) A community-based study design would be theo-
retically preferable. However, it is neither logistically nor 
financially feasible to conduct a multi-stage community 
survey to recruit subjects for this relatively rare condi-
tion. Instead, we opted for a clinical prospective longitu-
dinal cohort study. 
 (2) A selection bias towards less disabled patients may 
occur due to the ambulatory setting of the study, i.e. pa-
tients must be able to visit the study centre; institutional-
ized patients are not included into the study or are ex-
cluded upon institutionalization.
 (3) A selection bias towards patients in the proximity 
of the specialized centre participating in the study. Even 
with eight participating centres, the cohort will probably 
not be fully representative of all German PD patients.
 (4) New criteria for PD-MCI and DLB are currently 
being developed by the Movement Disorder Task Force 
 [41] . This may change the classification of the patients 
and may therefore change the outcome of this study. 
 (5) The collection of data on medication, ancillary 
therapies, etc. of PD is based in part on a patient-reported 
questionnaire and service utilization data we used in this 
study are self-reported. Such study designs naturally suf-
fer from recall bias. Recall bias will particularly occur 
when infrequent resource use has to be remembered. Ad-
ditionally, with increased disease severity of the cognitive 
decline in PD patients, the ability to recall is reduced by 
the progression of the disease. Recall bias may lead to un-
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derestimates of total service use. This is especially impor-
tant in patients with severe cognitive decline. 
 In conclusion, this large study will help to discern dis-
tinct patterns in the development and progress of demen-
tia in patients with PD and identify variables associated 
with these patterns. This is especially important as de-
mentia is the main reason for nursing home placement 
 [54] and increased caregiver burden  [55] . Early interven-
tion in the identified risk factors may help to delay nursing 
home placement and will increase the quality of life of the 
patients and their caregivers but also reduce their burden 
to society  [56] . The more refined definition of cognitive 
domains affected by PD may help to develop better screen-
ing and diagnostic instruments and better therapeutic in-
terventions. Finally, we expect to identify new biomarkers 
and/or be able to evaluate and validate those in our large 
cohort for the different diagnoses. Researchers in other 
countries are welcome to join this effort. For maximal 
usefulness to patients and to the scientific community, the 
consortium has agreed to make available the complete da-
taset of this study for research purposes. 
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